SUMMARY The excretory fate and plasma level of thiomalate were studied after intramuscular administration of auro-14C-thiomalate to 3 patients with rheumatoid arthritis. The gold and the thiomalate parts separated in vivo, and the free thiomalate was excreted in the urine, rapidly at first and then slowly. After one day about 60% of the 14C-label had been recovered in the urine. The plasma level also declined rapidly. The results are in complete agreement with those previously described in animal experiments.
Recently we showed, using double isotope-labelled aurothiomalate (195Au-14C-thiomalate) that the gold and the thiomalate separate in vivo, resulting in protein-bound gold and release of free thiomalate.' About half of this thiol is excreted in the urine during the first day, and the remaining half is bound to tissue membranes and cells.
These experiments were all carried out on animals (mice and rats). In view of the biological effects of thiomalate2 and its possible antirheumatic activity it would be desirable also to study in detail the fate of the thiomalate part after intramuscular administration of aurothiomalate to man. The results of such a study are presented in this report.
Materials and methods
Highly purified 14C-labelled sodium aurothiomalate (Na2 Au i2, injected once every week). In addition the patients used acetylsalicylic acid or naproxene; the man was also on treatment with corticosteroids (2 5 mg prednisolone per day).
The patients were given an intramuscular injection of a weighed and exact amount of the "C-labelled aurothiomalate (about 30 mg of substance corresponding to about 23 ,uCi of radioactivity). Urine and blood samples were collected at intervals, and 14C activity was counted in a Packard Tri-Carb liquid scintillation spectrometer using Packard Instagel II scintillator cocktail. All results were corrected for quenching. The identity of the labelled compounds which were present in the urine and serum was confirmed by thin-layer chromatography as previously described.3
Results
The excretion curves (Fig. 1) show that the "C-label of the aurothiomalate is excreted at a rapid rate initially and then very slowly. After 22 hours about 62 % of the radioactivity had been recovered in the urine. Thin-layer chromatography showed that free thiomalate and thiomalate disulphide accounted for nearly all the "C-activity in the urine of all 3 patients. Fig. 2 shows the amount of "C-label present in blood plasma at different times after injections. The label is rapidly eliminated, and after one day as little as 0-3 % of the "C-activity remains in the plasma. Since 
Discussion
Analysis of the urine samples collected after injection of the auro-14C-thiomalate clearly shows that in man as in the animal experiments the gold and the thiomalate moieties separate in vivo, resulting in an initial rapid excretion of free thiomalate in the urine. Six to twelve hours after the intramuscular injection of the gold complex, the elimination of the "C-label in the urine is very slow, and at the same time the amount of label circulating in plasma is very low. These results closely parallel those found in the case of mice' and reflect that a considerable portion (about 40 % of the injected dose) of the thiomalate has become bound to tissue membranes and cells. In view of these results and the recently demonstrated effects of thiomalate in in-vitro systems2 it is probable that part of the drug action of Myocrisin in man is due to the thiomalate. Preliminary clinical trial indicates that thiomalate may have an antirheumatic effect.4 
